Skip to content
    JNJ
    Earnings call· Jun 2025(Q2 FY25)

    JOHNSON & JOHNSON Q2 FY25 earnings call JNJ

    Jul 16, 2025 Source

    Executive summary

    Johnson & Johnson Q2 FY25 — Strong Diversified Growth and Raised Outlook

    Johnson & Johnson delivered a robust second quarter, showcasing the strength of its diversified Innovative Medicine and MedTech portfolios. Despite significant headwinds from STELARA's loss of exclusivity and Part D redesign, the company achieved strong operational sales growth and raised its full-year sales and EPS guidance. Management emphasized innovation and pipeline progress as key drivers for sustained growth through the end of the decade.

    Highlights

    5
    • Operational sales grew 4.6% across the business, despite a 710 basis point headwind from STELARA.

    • Innovative Medicine achieved over $15 billion in quarterly sales for the first time, with 3.8% operational growth despite a 1,170 basis point STELARA headwind.

    • MedTech delivered 6.1% operational sales growth, driven by Cardiovascular (22% growth), Surgery, and Vision.

    • Full-year sales guidance raised by $2 billion to a midpoint of $93.4 billion, representing 5.4% reported growth.

    • Adjusted EPS guidance raised by $0.25 to $10.85 at the midpoint, reflecting 8.7% growth.

    Concerns

    5
    • STELARA declined by 43.2% due to biosimilar competition and Part D redesign, in line with expectations.

    • Adjusted net earnings decreased 2.1% and adjusted diluted EPS decreased 1.8% due to interest from the Intra-Cellular acquisition and STELARA GP erosion.

    • Long-acting injectables declined 6.3% due to Part D redesign and unfavorable patient mix.

    • Orthopedics business declined 1.6% due to competitive pressures, transformation program, and China VBP.

    • MedTech margin declined from 25.7% to 22.2% due to macroeconomic factors, COGS, and other income.

    Guidance & targets

    19
    CategoryTargetConfidence
    Full-year operational sales growth
    4.5% to 5%
    high materiality
    High
    Full-year reported sales growth
    5.1% to 5.6%
    high materiality
    High
    Full-year adjusted operational sales growth (excluding A&D)
    3.2% to 3.7%
    medium materiality
    High
    Full-year adjusted diluted EPS
    $10.80 to $10.90
    high materiality
    High
    Full-year adjusted operational EPS
    $10.68
    medium materiality
    High
    Full-year operating margin
    Approximate 300 basis points improvement
    medium materiality
    High
    Full-year tariff impact
    $200 million
    medium materiality
    High
    Full-year net interest expense
    $0 to $100 million
    low materiality
    High
    Full-year effective tax rate
    17% to 17.5%
    medium materiality
    High
    GILTI tax rate increase
    Approximate 1% increase to global effective tax rate
    medium materiality
    High
    Oncology sales
    More than $50 billion
    high materiality
    High
    TAR-200 annual peak year sales
    At least $5 billion
    high materiality
    High
    TREMFYA annual peak year sales
    At least $10 billion
    high materiality
    High
    CAPLYTA peak year sales
    $5 billion-plus
    medium materiality
    High
    Shockwave MedTech platform value
    $13 billion
    medium materiality
    High
    Innovative Medicine operational sales growth
    Higher in H2 vs H1
    medium materiality
    High
    MedTech operational sales growth
    Higher in H2 vs H1
    medium materiality
    High
    STELARA biosimilar competition erosion
    Similar to HUMIRA's in year 2
    medium materiality
    High
    MedTech business growth
    5% to 7%
    medium materiality
    High

    Segment performance

    9
    SegmentRevenueYoYQoQMargin
    Innovative Medicine
    Achieved over $15 billion in quarterly sales for the first time. Growth outside the U.S. negatively impacted by STELARA biosimilars and COVID-19 vaccine. Margin declined from 44.6% due to negative mix and COGS related to STELARA.
    US Growth: 7.6%Outside US Growth: -1.6%STELARA Headwind: 1,170 bpsAcquisitions/Divestitures Net Positive Impact: 140 bps
    $15.2B3.8%42.7%
    Innovative Medicine - Oncology
    Strong performance across multiple myeloma, prostate cancer, and lung cancer. CARVYKTI growth driven by share gains and capacity expansion. TECVAYLI and TALVEY bolstered by community setting expansion. RYBREVANT plus LAZCLUZE driven by strong launch uptake.
    DARZALEX Growth: 21.5%DARZALEX Share Gains: ~4.1 points (across all lines), ~8 points (frontline)CARVYKTI Sales: $439MCARVYKTI Growth: >100%CARVYKTI Sequential Growth: 17.9%TECVAYLI and TALVEY Growth: 22.4% and 54.3%ERLEADA Growth: 21%RYBREVANT plus LAZCLUZE Sales: $179MRYBREVANT plus LAZCLUZE Growth: >100%RYBREVANT plus LAZCLUZE Sequential Growth: 26.5%
    22.3%
    Innovative Medicine - Immunology
    TREMFYA growth driven by share gains and strong uptake in IBD indications. STELARA decline due to biosimilar competition and Part D redesign, in line with expectations.
    TREMFYA Growth: 30.1%STELARA Decline: 43.2%
    Innovative Medicine - Neuroscience
    SPRAVATO growth driven by strong demand. Long-acting injectables declined due to Part D redesign and unfavorable patient mix.
    SPRAVATO Growth: 53%Long-acting Injectables Decline: 6.3%
    MedTech
    Driven by strong performance in Cardiovascular, Surgery, and Vision. Margin declined from 25.7% due to macroeconomic factors, COGS, and other income.
    US Growth: 8%Outside US Growth: 4.1%Acquisitions/Divestitures Net Positive Impact: 200 bps
    $8.5B6.1%22.2%
    MedTech - Cardiovascular
    Electrophysiology growth driven by competitive mapping, new product performance, and procedure growth. Abiomed growth from strong adoption of Impella technology. Shockwave delivered strong double-digit growth with new Javelin and E8 catheters.
    Electrophysiology Growth: 9.8%Abiomed Growth: 16.9%
    22%
    MedTech - Surgery
    Performance driven by technology penetration in wound closure and strength in Biosurgery. Partially offset by competitive pressures in energy and negative impact of China VBP.
    Divestitures Negative Impact: ~60 bps
    1.8%
    MedTech - Vision
    Contact lenses growth driven by strategic price actions and ACUVUE OASYS 1-Day family. Surgical vision growth driven by TECNIS Odyssey, TECNIS PureSee, and Eyhance.
    Contact Lenses and Other Ocular Products Growth: 2.9%Surgical Vision Growth: 8.9%
    4.6%
    MedTech - Orthopedics
    Declined due to competitive pressures, transformation program, and China VBP.
    -1.6%

    Operational metrics

    20
    Worldwide sales
    $23.7B
    Q2 FY25

    Total worldwide sales for the quarter.

    Operational sales growth
    4.6%
    Q2 FY25

    Despite an approximate 710 basis point headwind from STELARA.

    US sales growth
    7.8%
    Q2 FY25

    Growth in the U.S.

    Outside US sales growth
    0.6%
    Q2 FY25

    Growth outside of the U.S.

    Acquisitions and divestitures impact on worldwide growth
    160 bpspositive
    Q2 FY25

    Primarily due to the Intra-Cellular and Shockwave acquisitions.

    Adjusted net earnings
    $6.7B-2.1% YoY
    Q2 FY25

    Decrease driven by interest associated with incremental debt from Intra-Cellular acquisition and GP erosion from STELARA.

    Adjusted diluted EPS
    $2.77-1.8% YoY
    Q2 FY25

    Decrease driven by interest associated with incremental debt from Intra-Cellular acquisition and GP erosion from STELARA.

    Cost of products sold deleverage
    150 bps
    Q2 FY25

    Driven by product mix and amortization related to Intra-Cellular acquisition and MedTech macroeconomic factors and VBP in China.

    Selling, marketing and administrative expenses improvement
    50 bps
    Q2 FY25

    Driven by corporate expense rationalization, partially offset by increased investment in recent acquisitions.

    Research and development expenses leverage
    50 bps
    Q2 FY25

    Primarily driven by portfolio rationalization and expense phasing in MedTech.

    Research and development spend
    $3.5B
    Q2 FY25

    Continued strong investment in R&D.

    Net interest expense
    $48Mvs $125M income in Q2 2024
    Q2 FY25

    Primarily driven by lower rates of interest on cash balances and a higher average debt balance associated with the Intra-Cellular acquisition.

    Other income and expense
    $0.1B expensevs $0.7B expense in prior year
    Q2 FY25

    Primarily driven by lower talc litigation expense in 2025 and the $0.4 billion loss on the sale of the retained stake in Kenvue shares recorded in 2024.

    Effective tax rate
    14.7%vs 18.5% in Q2 2024
    Q2 FY25

    Compared to the same period last year.

    Cash and marketable securities
    $19B
    Q2 FY25 end

    Balance at the end of the second quarter.

    Debt
    $51B
    Q2 FY25 end

    Balance at the end of the second quarter, includes debt for Intra-Cellular acquisition.

    Net debt
    $32B
    Q2 FY25 end

    Balance at the end of the second quarter.

    US investment commitment
    $55B
    Next 4 years

    Commitment to invest in the United States, enabled by the One Big Beautiful Bill Act.

    VARIPULSE cases
    10,000+
    Cumulative

    Completed globally with reported neurovascular event rate consistent with published rates across other PsA platforms.

    CARTO systems installed base
    5,000
    Current

    Widely recognized as the benchmark in mapping software.

    Industry KPIs

    9
    MetricValueDetails
    Peak sales guidance$5B+USD
    EPS revenue guidance$93.4BUSD
    Pricing policy impactUnfavorable impact
    Product franchise net sales22.3%%
    Pipeline clinical milestones25+treatments
    Regulatory approvals filingsFDA priority review
    Therapeutic drug market share4.1 pointspoints
    Geographic regional revenue growth7.8%%
    Clinical trial efficacy safety data100%%

    Product announcements

    8
    ProductTypeDetails
    Ethicon 4000 surgical staplerlaunch
    ACUVUE OASYS MAX 1-Day MULTIFOCAL for astigmatismlaunch
    Dual Energy THERMOCOOL SMARTTOUCH SF Catheterlaunch
    Javelin and E8 catheters (Shockwave)launch
    ATTUNE Revision Hinge and Vault plating systemlaunch
    KINCISE 2.0launch
    VELYS Spine Robotlaunch
    TriALTISlaunch

    Deals & partnerships

    2
    Intra-Cellular TherapiesAcquisition of a company focused on neuroscience therapies.$14.5B

    Acquisition closed on April 2, 2025. Added CAPLYTA, approved to treat adults with schizophrenia and bipolar depression.

    ShockwaveAcquisition of a company with intravascular lithotripsy technology.

    Acquisition benefit was lapped to the end of May. Driving significant growth in Cardiovascular.

    Risks & headwinds

    8
    STELARA loss of exclusivity (LOE) and biosimilar competitionQ2 FY25 and accelerating throughout FY25

    710 bps headwind to total operational sales growth; 1,170 bps headwind to Innovative Medicine operational sales growth; 43.2% decline in STELARA sales.

    Mitigation: Diversified portfolio, strong performance of other brands and new launches.

    Part D redesign impactFY25

    Contributed to STELARA decline and long-acting injectables decline (6.3%).

    Mitigation: Not explicitly stated, but managed within overall guidance.

    Interest associated with Intra-Cellular acquisition debtQ2 FY25

    Contributed to decrease in adjusted net earnings and adjusted diluted EPS; higher average debt balance.

    Mitigation: Managed within financial outlook, net interest expense guidance improved due to higher interest on cash balances.

    Talc litigation expenseQ2 FY25

    Lower expense in 2025 compared to prior year ($0.1B vs $0.7B).

    Mitigation: Anticipating Daubert hearing to reexamine scientific evidence.

    Tariff impactFY25

    Anticipated $200 million impact for FY25 (down from $400 million), exclusively related to MedTech.

    Mitigation: Differential reinvested into pipeline and new product launches; goal to manufacture all US-consumed medicines domestically.

    Competitive pressures in MedTechQ2 FY25

    Partially offset Surgery growth (energy segment); contributed to Orthopedics decline (1.6%).

    Mitigation: New product launches (Ethicon 4000, OTTAVA, VELYS Uni Knee, ATTUNE Revision Hinge, KINCISE 2.0, VELYS Spine Robot, TriALTIS), focus on differentiated innovation.

    China VBP (Volume-Based Procurement)Q2 FY25

    Negative impact on Surgery and Orthopedics.

    Mitigation: Not explicitly stated, but managed within overall segment performance.

    Macroeconomic factorsQ2 FY25

    Contributed to MedTech margin decline.

    Mitigation: Not explicitly stated, but managed within overall financial performance.

    What to watch in Q3 FY25

    5

    TAR-200 launch progress

    H2 FY25
    CurrentFDA priority review received; anticipated launch later this year
    TargetSuccessful launch and initial uptake in high-risk non-muscle invasive bladder cancer

    Why it matters

    TAR-200 is a transformational product with expected peak sales of at least $5 billion, representing a significant growth driver and a major disconnect with Street expectations.

    We anticipate launching TAR-200 for high-risk non-muscle invasive bladder cancer later this year, a transformational product that harnesses our unique expertise in both Innovative Medicine and MedTech. We expect TAR-200 to generate at least $5 billion in annual peak year sales.

    Q&A highlights

    7

    What were the primary drivers for the strong top-line beat and the raised guidance for the year, specifically asking about contributions from Innovative Medicine versus MedTech and key franchises?

    Management confirmed both Innovative Medicine and MedTech contributed significantly. Innovative Medicine saw robust growth (15.5% excluding STELARA) with 13 double-digit growing brands, including DARZALEX, CARVYKTI, ERLEADA, RYBREVANT+LAZCLUZE, TREMFYA, SPRAVATO, and CAPLYTA. MedTech's 6.1% growth was driven by Cardiovascular (22%), Vision, and Surgery, with strong performance in Abiomed, Shockwave, and electrophysiology. They expect continued acceleration in H2 due to new product launches and easier comparables.

    If you take a look at the 90% of our business that is not STELARA, we actually had extraordinarily robust growth of 15.5% growth, really demonstrating the strength across our portfolio.

    asked by Christopher Schott · answered by Jennifer Taubert

    3 min read6 chapters

    Detailed Narrative

    01

    Oncology Portfolio Strength and Pipeline

    Johnson & Johnson is on track to become the #1 oncology company by 2030 with over $50 billion in sales, driven by 22.3% operational sales growth in Q2. Key progress includes multiple myeloma treatments like DARZALEX, CARVYKTI (sales of $439M, >100% growth), TECVAYLI, and TALVEY, with new 5-year data for CARVYKTI showing long-term remission and 100% ORR for an investigational trispecific antibody. In lung cancer, RYBREVANT plus LAZCLUZE delivered $179M in sales with >100% growth, showing strong launch uptake and intent to prescribe. The company also received FDA priority review for TAR-200 in bladder cancer, anticipating a launch later this year with expected peak sales of at least $5 billion.

    02

    Immunology Innovation and Growth

    The Immunology portfolio continues to expand treatment options, with TREMFYA growing 30% in the quarter, driven by strong uptake in Crohn's disease and ulcerative colitis. TREMFYA is expected to generate at least $10 billion annually in peak year sales. The company plans to file icotrokinra, a targeted oral peptide for plaque psoriasis, with the FDA in Q3, which has shown similar efficacy to biologics and has potential in ulcerative colitis. This highlights a strategy of moving beyond traditional biologics to oral therapies and co-antibody approaches.

    03

    Neuroscience Expansion and Market Leadership

    J&J aims to be the #1 Neuroscience company by the end of the decade. SPRAVATO grew 53% in Q2, demonstrating strong demand for difficult-to-treat depression. The acquisition of Intra-Cellular Therapies added CAPLYTA, approved for schizophrenia and bipolar depression, with an anticipated major depressive disorder approval later this year. CAPLYTA is expected to achieve over $5 billion in peak year sales, solidifying growth above analyst expectations.

    04

    MedTech Cardiovascular Momentum

    Cardiovascular delivered over 22% operational sales growth in Q2, making J&J a leader in this fast-growing MedTech segment. This was driven by new product performance in Abiomed (16.9% growth) and Shockwave, as well as strength in electrophysiology (9.8% growth). The company has completed over 10,000 VARIPULSE cases globally with a low neurovascular event rate and is advancing solutions like the Dual Energy THERMOCOOL SMARTTOUCH SF Catheter and OMNYPULSE. Shockwave's IVL technology is expected to be a $13 billion MedTech platform by year-end.

    05

    Surgery and Vision Portfolio Performance

    Surgery grew 1.8%, supported by technology penetration in wound closure and Biosurgery, despite competitive pressures and China VBP. The Ethicon 4000 surgical stapler was introduced, and the OTTAVA robotic surgery system completed its first clinical cases, with an FDA de novo submission planned for next year. Vision saw 4.6% growth, with surgical vision up 8.9%, driven by ACUVUE OASYS MAX 1-Day contact lenses and TECNIS Odyssey/PureSee IOLs. The launch of the first disposable multifocal lenses for astigmatism is expected to further boost growth.

    06

    Financial Outlook and Strategic Investments

    The company raised its full-year sales guidance by $2 billion and EPS guidance by $0.25, reflecting strong Q2 performance and favorable FX. The full-year operating margin improvement of approximately 300 basis points was reiterated. The anticipated tariff impact🌐 for 2025 was reduced from $400 million to $200 million, with the differential reinvested into pipeline acceleration. J&J reaffirmed its commitment to invest $55 billion in the U.S. over the next four years, supported by recent tax policies, aiming to manufacture all U.S.-consumed medicines domestically.

    AI-generated summary of the company’s earnings call. Not investment advice.